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Abstract
Background: Mumps virus V protein has the ability to inhibit the interferon-mediated antiviral response by
inducing degradation of STAT proteins. Two virus variants purified from Urabe AM9 mumps virus vaccine differ in
their replication and transcription efficiency in cells primed with interferon. Virus susceptibility to IFN was
associated with insertion of a non-coded glycine at position 156 in the V protein (VGly) of one virus variant,
whereas resistance to IFN was associated with preservation of wild-type phenotype in the V protein (VWT) of the
other variant.
Results: VWT and VGly variants of mumps virus were cloned and sequenced from Urabe AM9 vaccine strain. VGly
differs from VWT protein because it possesses an amino acid change Gln103Pro (Pro
103) and the Gly156 insertion.
The effect of V protein variants on components of the interferon-stimulated gene factor 3 (ISGF3), STAT1 and
STAT2 proteins were experimentally tested in cervical carcinoma cell lines. Expression of VWT protein decreased
STAT1 phosphorylation, whereas VGly had no inhibitory effect on either STAT1 or STAT2 phosphorylation. For
theoretical analysis of the interaction between V proteins and STAT proteins, 3D structural models of VWT and VGly
were predicted by comparing with simian virus 5 (SV5) V protein structure in complex with STAT1-STAT2
heterodimer. In silico analysis showed that VWT-STAT1-STAT2 complex occurs through the V protein Trp-motif
(W174, W178, W189) and Glu95 residue close to the Arg409 and Lys415 of the nuclear localization signal (NLS) of STAT2,
leaving exposed STAT1 Lys residues (K85, K87, K296, K413, K525, K679, K685), which are susceptible to proteasome
degradation. In contrast, the interaction between VGly and STAT1-STAT2 heterodimer occurs in a region far from
the NLS of STAT2 without blocking of Lys residues in both STAT1 and STAT2.
Conclusions: Our results suggest that VWT protein of Urabe AM9 strain of mumps virus may be more efficient
than VGly to inactivate both the IFN signaling pathway and antiviral response due to differences in their finest
molecular interaction with STAT proteins.
Background
Interferon induces the major defense against viral infec-
tions. It begins with attachment of IFN-a or -b to het-
erodimeric receptors composed of IFNAR1 and IFNAR2
subunits whose intracellular domains are associated with
Tyk2 and Jak1 tyrosine kinases, respectively [1]. Activa-
tion of the signal transduction occurs when Tyk2
phosphorylates Tyr466 residue on IFNAR1, creating a
docking site for STAT2 that is phosphorylated on
Tyr690. Phosphorylated STAT2 protein then associates
with STAT2, inducing its phosphorylation on Tyr701 by
JAK1 [2,3]. STAT1 and STAT2 form a heterodimer that
creates a nuclear localization signal (NLS). STAT1-
STAT2 heterodimers result from intermolecular interac-
tions between Src homology 2 (SH2) domains and
phosphorylated Tyr residues at each protein [4]. In addi-
tion, IFNAR2 subunit is acetylated at Lys399 and pro-
motes the acetylation of IRF9, which is essential to
DNA binding [5,6]. Association of STAT1-STAT2
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heterodimer with IRF9 constitutes the IFN-stimulated
gene factor 3 (ISGF3) transcription factor, which binds
to IFN-stimulated response elements (ISRE) at IFN-sti-
mulated genes (ISG). The final step of this signaling
pathway is the induction of gene transcription whose
expression establishes the antiviral state [2,7]. Several
viruses have evolved strategies to circumvent the anti-
viral state stimulated by IFN through the expression of
proteins that antagonize some components of the IFN
signaling pathway such as the V protein of paramyxo-
viruses [8]. Mumps virus P gene codes for three poly-
peptides: V, I and P. Their mRNAs are translated by use
of overlapping reading frames (ORFs) via cotranscrip-
tional insertion of nontemplated guanidine nucleotides
(mRNA edition) [9,10]. Mumps virus V protein is a
nonstructural protein that counteracts the IFN-induced
antiviral response [11].
Paramyxovirus V proteins possess an identical
N-terminal sequence with P and I proteins but have a
unique C-terminal that contains two functional motifs
[9]. The first is the cysteine-rich (Cys-rich) motif
(CX3CX11CXCX2CX3CX2C) where × refers to any
amino acid residue that establishes a stoichiometric rela-
tionship (1:2) with Zn2+. Cys-rich motif is highly con-
served among rubulaviruses such as simian virus 5
(SV5), simian virus 41 (SV41), human parainfluenza
virus type 2 (hPIV2), and mumps virus. Cys-rich motif
promotes the formation of an oligomer that acts as a
nucleation site known as V-dependent degradation
complex (VDC) where both polyubiquitylation and
degradation of STAT1 occur [12,13]. The V proteins of
mumps virus and SV5 induce the degradation of STAT1
protein through the VDC assembly that includes ubiqui-
tin ligase E3, Roc1, Cul4A, and DDB1 proteins that
facilitate polyubiquitylation of STAT1 [13,14]. The sec-
ond C-terminal motif is also involved in STAT1 degra-
dation and is a Trp-motif (W-(X)3-W-(X)9-W) that
includes W174, W178 and W188 residues located
upstream of the Cys-rich motif [15,16]. The C-terminal
of V protein is essential for successful viral infection by
inhibition of IFN signaling and blocking of the antiviral
response [17]. In this study we analyzed two variants of
mumps virus V protein (VWT and VGly) derived from
Urabe AM9 vaccine strain. Previous studies have shown
that Urabe AM9 vaccine is constituted by several quasis-
pecies that differ in distinct sites all along their gen-
omes. We purified two virus variants based on the
sequence of their HN gene and were named HN-A1081
and HN-G1081, which codes for HN-K335 and HN-
E335 proteins, respectively. Several studies have related
HN-A1081 with neurovirulence because this virus var-
iant was frequently isolated from patients with postvac-
cine aseptic meningitis [18]. We demonstrated that HN-
A1081 variant preferentially infects nerve cells, whereas
HN-G1081 variant has limited replication in nerve cells.
Selective infection of nerve cells was associated with dif-
ferences in the virus binding affinity towards cell recep-
tors [19]. However, further experiments showed that
differences in sensitivity to IFN determined the replica-
tion rate of Urabe AM9 mumps virus variants in nerve
cells. Indeed, HN-A1081 virus variant evaded the IFN-
induced antiviral response and replicated in cells primed
with IFN, whereas HN-G1081 variant reduced both
replication and transcription in IFN-primed cells [20].
Sensitivity to IFN was associated with insertion of a
non-coded glycine at position 156 in the V protein
(VGly) of HN-G1081 virus variant, whereas resistance to
IFN was associated with preservation of wild-type phe-
notype in the V protein (VWT) of HN-A1081 Virus var-
iant. In the present study we experimentally tested the
interaction of VWT and VGly proteins of Urabe AM9
mumps virus variants with proteins of the IFN signaling
pathway, finding differences in their capacity to bind
STAT proteins. In addition, in silico three- dimensional
structure models of VWT and VGly proteins supported
their difference to form complexes with STAT1 and
STAT2 in vitro. The relevance of these theoretical find-
ings in the function of V protein and virulence of
mumps virus variants are discussed.
Results
In order to determine the effect of protein V of the
majority populations that comprise the Urabe AM9 vac-
cine strain on the IFN pathway, we obtained the coding
region for V proteins from HN-A1081 and HN-G1081
virus variants, which were cloned in the pcDNA4/His-
Max TOPO vector (pcDNA4/HisMaxVA and pcDNA4/
HisMaxVG) to add a His-tag at the amino end. Next,
the full sequence of V ORF was determined (675 bp),
and in silico translation was carried out by comparative
analysis. Amino acid differences between V proteins
were determined by comparison with the V protein
from Urabe AM9 (SmithKline Beecham) (Protein:
AAK60067.1). The VA protein containing only 224 resi-
dues similar to the wild-type V protein type was named
VWT (28.17 kDa). The VG protein contained two
changes on residue 103, Q®P, and the addition of a gly-
cine residue at position 156, which generated a V pro-
tein with 225 amino acids and was designated VGly
(28.13 kDa). Comparing both V proteins, there were no
significant changes in the theoretical physicochemical
parameters.
To determine the effect of VWT and VGly proteins
on the IFN pathway, they were expressed in cervical car-
cinoma cells stimulated with IFN-a2b. First we deter-
mined the ISGF3 complex formation in response to
IFN-a2b by detecting STAT1, STAT2 and IRF9 proteins
in cells stimulated with IFN and the proteasome
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Figure 1 Decrease in pY701-STAT-1 level protein by VWT of Urabe AM9 vaccine strain. (A) Detection of ISGF3 complex activated by IFN-a
in human cervical carcinoma cell line. The complex was determined 48 h after transfection and 6 h after stimulation with IFN proteins separated
by 7% PAGE under native conditions, semidry transfer to PVDF membrane and immunodetection with specific antibodies for pTyr701-STAT1
proteins, pTyr690-STAT2 and IRF9 (ISGF-g3). The molecular weight of the complex is 250 kDa. (B) Effect of VWT and VGly proteins on STAT1 and
STAT2 phosphorylated proteins by Western blot in human cervical carcinoma cell line. Proteins were separated in 10% SDSPAGE with semidry
transfer to PVDF membrane and immunodetection with antibodies against His-tag for V proteins, pTyr701-STAT1, pTyr690-STAT2 and b-actin. (C)
Detection of STAT1 inactive protein in cell expressing VWT and VGly proteins and 10% SDS-PAGE transfer to PVDF membrane and
immunodetection with antibodies against STAT1 inactive protein and b-actin to normalize the level protein.
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inhibitor MG132. Figure 1A shows the ISGF3 complex
of 250 kDa identified with the three antibodies used.
This result indicates the ability of the cells to activate
the antiviral IFN pathway. Next we examined the effect
of V protein on the level of Y701-STAT1 and Y690-
STAT2 phosphorylated proteins. Figure 1B demon-
strates that cells expressing protein VWT decreased
phosphorylated STAT1 protein.
None of the variants changed the level of active
STAT2 protein as determined with other strains of
mumps virus. To test whether the result in Figure 1B
was due only to reduction of active STAT1 protein or
by degradation of STAT1 unphosphorylated protein, we
studied the level of inactive STAT1. Figure 1C shows
that in cells expressing VWT and VGly proteins there
are no changes in the level of STAT1 protein. This sug-
gests that VWT protein of Urabe AM9 affects the
STAT1 phosphorylated protein in blocking type I IFN
system. In other strains of mumps virus and SV5, reduc-
tion of the STAT1 protein was always determined in the
heterodimer with STAT2 phosphorylated protein with
the subsequent blockade of the IFN system [21]. Figure
1B, C suggests a differential effect of the V proteins of
Urabe AM9 strain vaccine on antiviral cellular response,
which may be due to different interactions of VWT and
VGly proteins with STAT1-STAT2 heterodimer.
To analyze this assumption we studied the theoretical
interaction between VWT and VGly proteins and IFN
pathway proteins. Theoretical 3D structure prediction of
VWT and VGly was first performed by homology using
the tertiary structure of V-SV5, PDB: 2B5Lc [22], which
lack three loops in positions 1-15, 55-80 and 153-159.
The identity of VWT and VGly with the template was
39%. The 3D model of VWT originates in amino acid
37 and ends in 220 (183 residues), whereas the VGly
model originates in position 37 and ends in 221 (184
residues). Qualitative values of the 3D models were in
the expected region for structural models of proteins
with values of PROSA Z-score as follows: -2.71, -2.35
and -2.47 for VWT, VGly and V-SV5, respectively, used
as template protein. Theoretical 3D structure of VWT
and VGly proteins can be described as an N-terminal
domain, which adopts an a-helical structure (a1), a core
domain with a central seven-stranded b sheet rounded
by an a helix (a2) and two loops in the C-terminal end
(Figure 2A, 2B). To observe the differences between 3D
models in both proteins, we performed a superimposi-
tion of structures. Figure 2C shows the theoretical
changes in the 3D models. In VGly there is an arrange-
ment of loops connecting b3 and b4 strands such as the
loop between b6 and b7 where Gly156 was inserted,
although the most evident modification is the subse-
quent region to the Gly insertion where the Cys-rich
motif is located (amino acids in pink, Figure 2C). The
presence of Pro103 in VGly (residues in orange and yel-
low in Figure 2C) does not significantly modify the the-
oretical structure of the V protein. All residues of the
Trp-motif were modified in regard to Trp-motif in
VWT (amino acids in purple, Figure 2C).
For the formation of STAT1-STAT2 heterodimer acti-
vated by IFN, the 3D structure of STAT1 was obtained
from PDB: 1YVL (structure of unphosphorylated STAT1)
[23] and the 3D theoretical model of STAT2 by homol-
ogy from templates PDB: 1BF5 (tyrosine phosphorylated
STAT-1/DNA complex) [24] and PDB: 1YVL with the
purpose of obtaining the 3D model that includes Tyr690
required for interaction with STAT1 (identity was 46%
with STAT1). According to the analysis, the site of inter-
action on the receptor (STAT2) was set in positions 690
and 698 and the ligand binding site (STAT1) was set in
positions 701 and 708, which included the amino acids
Tyr690 and Tyr701 of STAT2 and STAT1, respectively, to
achieve formation of the dimer by interaction of their
SH2-domains (573- 670 in STAT1 and 572-667 in
STAT2). The model of STAT1-STAT2 dimer corre-
sponded to the solution of lowest overall energy (-43.71)
with attractive and repulsive van der Waals energy of
-29.86 and 14.05, respectively; an atomic contact energy
of -5.27 and an energy of -3.35 derived from formation
of hydrogen bonds. Construction of this model was based
on the phosphorylated STAT1 model [24]. The following
were located in the heterodimer model (Figure 3A): resi-
dues of Tyr690 and Tyr701 (orange) and NLS residues in
STAT1: Lys410 and Lys413, in STAT2 Arg409 and Lys415
(pink), potential ubiquitylation sites in STAT1 (K85, K87,
K296, K413, K525, K679, K685) and STAT2 (K178, K182, K543,
K681) (blue). Next we analyzed the model of interaction
between V proteins and STAT proteins. The VWT-
STATs complex had an overall binding energy of -57.08
with atomic contact energy of -1.43, attractive and repul-
sive van der Waals energy of -68.32 and 34.70, respec-
tively, and energy of -4.38 derived from the formation of
hydrogen bonds. In the interaction model of VWT-
STATs complex, that interaction occurs through STAT2
near Arg409 and Lys415 of NLS without interference from
amino acids Lys410 and Lys413 in NLS of STAT1 (Figure
3B, checkbox). The analysis showed that the interaction
occurs through the Trp-motif and Glu95 (residue equiva-
lent to Asn100 of V-SV5 that interacts with STAT2). In
V-SV5, the change from Asn100®Asp100 maintained the
ability of interaction with STAT2 [25]. In mumps virus V
protein, the relatively conservative conversion of glutamic
acid to an aspartic acid (E95D) resulted in a V protein
still capable of blocking STAT1 signaling [26]. Several
studies demonstrated that the mumps virus V protein
requires STAT2 to promote the degradation of STAT1
through the proteasome [13,21,27]. We hypothesize that
the association of V with STAT2 would leave STAT1
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Figure 2 Homologous modeling and differences of theoretical 3D structure of VWT and VGly. (A) Models of V proteins, VWT and (B) VGly
built with the PDB: 2B5Lc as template. Both cases show residues 155 and 103. Additionally, residue 156 is shown in B. (C) Superimposition of
the 3D models of VWT (gray) and VGly (blue), Gly155 (green), Gly156 of VGly (red), Pro103 of VGly (orange), Gln103 of VWT (yellow), Trp-motif
residues of binding to STAT1-STAT2 (purple), Cys-rich motif C4HC3 (residues in pink). Display in Web Lab Viewer.
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Figure 3 Interaction model V-STAT1-STAT2. (A) Heterodimer model of STAT1-STAT2 by the SH2-domain (STAT1 PDB: 1YVL and 3D model of
STAT2 from 1YVL and 1BF5). Heterodimer model shows the following residues: Tyr690 and Tyr701 (orange), nuclear localization signal residues
(pink), lysine residues to ubiquitylation (Ub) (blue). (B) Interaction of STATs heterodimer with VWT by Trp-motif and STAT2. (C) Interaction of
heterodimer with VGly by STAT2, lysine residues (Ub) (blue). In B and C, the boxes at right show the interaction site.
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susceptible to ubiquitination. The seven potential ubiqui-
tylation sites in STAT1 would not be blocked by the
association with VWT. The model VGly-STATs complex
had an overall energy of interaction of -92.74, atomic
contact energy of -11.21, attractive and repulsive van der
Waals energy of -54.45 and 22.00, respectively, and
energy of -4.24 derived from the formation of hydrogen
bonds. In the theoretical model of VGly-STATs complex,
the interaction occurs through STAT2 but far from the
NLS of STAT1 and STAT2 (Figure 3C, box). However,
the contact among proteins does not occur due to the
Trp-motif or Glu95 (Figure 3C). On the other hand, the
interaction of VGly with the heterodimer does not pre-
vent ubiquitylation of the lysine residues of both STAT1
and STAT2, although two Lys amino acids (178 and 182)
are near the interaction site of VGly with STAT2.
Discussion
The lack of antiviral for specific control of mumps virus
infection requires the study of the molecular mechanism
of replication and viral expression to propose sites
related to the blocking of viral infection. The Urabe
AM9 mumps vaccine is associated with virulence and is
composed of at least two viral variants [18,28,29]. HN-
A1081 variant selectively and preferentially infects nerve
cells, whereas HN-G1081 has limited replication in
these cells. It is interesting to explore the differences of
the potential determinants of a successful viral infection
in the nervous system [18,19]. Considering that V pro-
tein of the Paramyxoviridae family is a factor that facili-
tates viral replication by blocking certain steps in the
IFN pathway, there may be a difference between V pro-
teins from Urabe AM9. We currently know that the V
protein from wild-type mumps virus, Torri and Enders
strains, is associated with STAT1-STAT2 to prevent
antiviral cellular response [11,13,30,31].
In this study we analyzed both in vitro and in silico two
variants of V protein Urabe AM9: VWT (related to asep-
tic meningitis) and VGly. Amino acid sequence analysis
showed that VGly is different from VWT at Pro103 and
Gly156. Such changes altered the theoretical 3D structure
and possibly its anti-IFN function. The analysis of the
effect of the V protein on STATs proteins showed the
efficiency of VWT protein to promote the reduction of
STAT1 active protein, whereas VGly protein did not
affect its level. This fact has been demonstrated in others
strains [13,21,26,31]. Such data suggest that the structural
changes on VGly induced by rearrangement of loops and
residues of the Cys-rich and Trp-motifs following the
addition of Gly156 may be responsible for the loss of effi-
ciency in inducing degradation of the STAT1 protein.
This could explain the differences reported in the replica-
tion and transcription of genes in response to interferon
during infection with the variant HN-G1081 (VGly) of
Urabe AM9 where the induction of genes in response to
interferon is higher than in the presence of an infection
with the variant HN-A1081 (VWT) [20]. However, we
cannot conclude if the changes induced by the addition
of Gly156 and the low efficiency in the degradation of
STAT1 protein for the variant VGly are conferred by
inefficient interaction with the proteins involved in the
ubiquitylation and degradation by the proteasome system
(E2, DDB1, Cullin, Roc1) [14]. These must be confirmed
experimentally. To outline a likely explanation, it was
predicted the theoretical 3D structure of VWT and VGly
by homology modeling. Although the 2B5Lc template
lack three loops not resolved by X-ray diffraction, the
program modeled two mobile loops but we cannot pro-
vide a conclusion of the modeled structure without the
template for comparison. The changes mentioned in the
VGly modified the theoretical 3D structure, particularly
in the loops that limit the Cys-rich motif. The residues of
these motifs in VGly move away from Gly155 (present in
both proteins), altering the 3D distribution. It is possible
that residues in Cys and Trp motifs of VWT are those
related to the activity anti-IFN of the V protein of Urabe
AM9 mumps vaccine.
At the experimental level, the intermolecular interac-
tion of mumps virus V protein and V-SV5 with the cel-
lular protein of type I IFN by the VDC complex has
been demonstrated: STAT1-STAT2 (both phosphory-
lated), DDB1, Cullin 4A and Roc1 [13]. Interestingly, the
interaction of VWT occurs through STAT2, an area
near NLS residues [32] that would prevent their impor-
tation to the nucleus by steric hindrance. The theoreti-
cal interaction with
STAT2 could maintain the heterodimer in the cyto-
plasm where the ubiquitin/proteasome labels the lysine-
susceptible residues exposed in STAT1. In vivo, it has
been shown that the promotion of degradation of STAT1
by the V protein of MuV and V-SV5 is dependent on
STAT2 in the VDC complex [13,14,21,26,33,34]. In any
case it would block signal transduction of type I IFN to
the nucleus, avoiding the antiviral cellular state favorable
to viral replication of HN-A1081 variant of Urabe AM9.
Instead, in silico analysis of the theoretical interaction
between VGly and STAT1-STAT2 showed that the con-
tact occurs through STAT2 as in VWT but in a region
far from residues of the NLS on STAT1/STAT2. This
would suggest that the heterodimer may advance to the
nucleus for exercising its transcriptional activity,
although the majority of lysine residues able to bind to
ubiquitin are exposed. Although the comparison of the
interaction parameters showed that the complex VGly
with the STATs proteins may be more stable in terms of
overall energy interaction, the attractive and repulsive
van der Waals forces were higher in the complex
between VWT and
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STAT1-STAT2 proteins. The data obtained would
explain the reduced capacity of VGly to block the IFN
transduction signal, generating a cellular environment
unfavorable for viral infection [27].
Conclusions
The in silico analysis suggests that, in vivo, VWT may
be more efficient than VGly to associate with the
STATs proteins and probably for blocking the IFN




The cervical carcinoma cell lines HeLa and C33A were
used for transfections assays and were maintained in
Dulbecco’s minimum essential medium (Sigma, St.
Louis, MO, USA) supplemented with 10% fetal bovine
serum (Gibco-BRL, Grand Island, NY), 100 U/mL peni-
cillin, 100 μg/mL streptomycin and 1% nonessential
amino acids (Sigma, St. Louis, MO, USA). Cells were
incubated at 37°C in 5% CO2.
Subcloning of VA and VG ORF
The cloning of VA and VG ORF were performed by PCR
from pCR-TOPO-VA and pCRTOPO-VG building in a
previous work [20] with the oligonucleotides MuV-1 D
5’-GACCAATTTATAAAACAAGATGAGACTGGT-3’
and MuV2 5’-TCCATCCCTCTAAGGAGGTCC-3’ (IDT,
Coralville, IA). PCR fragment was subcloned in the
pCDNA4/HisMax TOPO vector (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
This vector added a His-tag at the N-terminal of V pro-
teins. Recombinant DNA was transformed in E. coli TOP
10 One Shot (Invitrogen, Carlsbad, CA, USA). Positive
clones were sequenced by Big Dye ABI chemistry.
Transient transfection assay and IFN treatment
A monolayer of adenocarcinome cervix cells grown to
80% confluence on flasks of 25 cm2 was transfected with
6 μg of vector DNA (pCDNA4/His/Max-VA and VG)
and TurboFect transfection reagent (Fermentas, Glen
Burnie, MD, USA) according to the manufacturer’s
instructions. After cultivation for 24 h, the cells were
stimulated with the proteasome inhibitor MG132 (40
μM) (Sigma, St. Louis, MO, USA). At 42 h after trans-
fection, the cells were treated with 4000 IU/mL of IFN-
a2b (Urifrón) (Probiomed, Mexico) for 6 h.
Western Blot Analysis
After the stimulation with IFN-a2b and MG132, the cells
were lysed with ProteoJET Mammalian Cell Lysis
Reagent (Fermentas, Glen Burnie, MD, USA), and the
cell lysates were lyophilized and solubilized by boiling for
10 min with sodium dodecyl sulfate (SDS)-polyacryla-
mide gel electrophoresis (PAGE) sample buffer (62.5 mM
Tris-HCl pH 6.8, 5% 2-mercaptoethanol, 2% SDS, 0.005%
bromophenol blue, 10% glycerol). The proteins were
transferred to a PVDF membrane (0.45 μm) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The membrane
was treated with primary antibody (p-Tyr701 Stat1: sc-
7988, p-Tyr690 Stat2: sc-21689, ISGF-3 p48: sc-10793,
Actin: sc-8432, His-probe: sc-8036 (Santa Cruz Biotech-
nology) for 1 h and then incubated with the secondary
antibody (bovine antirabbit IgG-HRP: sc-2370) (Santa
Cruz Biotechnology) for 1 h. After extensive washing, the
immunoreactive bands were detected with Immobilon
Chemiluminiscent substrate (Millipore Corporation, Bed-
ford, MA, USA). For detection of the ISGF3 complex,
proteins were separated by electrophoresis through 7.5%
polyacrylamide gels, transferred to PDVF membranes,
and detected with the previously mentioned antibodies.
Generation and analysis of 3D protein models
The prediction for homology of the 3D protein structure
was performed with the Swiss-Model program [35]
using as template the structure of V protein simian
virus 5 (V-SV5) at 2.85 Å by X-ray diffraction [22].
Neighboring protein structures of mumps virus V pro-
teins were obtained with VAST search [36]. Theoretical
3D structure of VWT and VGly was visualized with
Web Lab Viewer program. The final theoretical 3D
structures were analyzed with PROCHEK of Swiss-
Model [37,38] and with PROSA [39]. The theoretical 3D
model of STAT2 was obtained for homology on
Geno3D [40] from the PDB: 1BF5 (Tyrosine phosphory-
lated STAT-1/DNA complex) [24] and PDB: 1YVL.
Electrostatic potential was obtained with the Poisson-
Boltzmann method in Deep View from Swiss PDB
Viewer. The differences between VWT and VGly were
analyzed in the SuperPose program [41]. Polyubiquityla-
tion sites in STATs proteins were predicted with Uni-
Pred [42], considering as probable those Lys residues
with a minimum score of 0.7 to 1.
Theoretical interaction
Theoretical heterodimer STAT1-STAT2 model was
obtained by a docking analysis with Hex server [43].
The putative interaction models between VWT and
VGly with STAT1-STAT2 proteins were generated with
PatchDock server (Molecular Docking Algorithm Based
on Shape Complementary Principles) [44] and 1000 the-
oretical models were refined on FireDock (Fast Interac-
tion Refinement in Molecular Docking) [45].
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